Last reviewed · How we verify
Metoprolol in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease
The goal of the clinical trial was to see if Metoprolol was effective in treating patients with heart failure and chronic obstructive pulmonary disease. It will also learn about the safety of Metoprolol. The main questions it aims to answer are: Did Metoprolol reduce the frequency of all-cause deaths and re-hospitalizations in subjects? What medical problems do participants experience after taking Metoprolol? The researchers will compare different doses of Metoprolol to see the best dose for Metoprolol. Participants will: Take Metoprolol 23.75mg/ day or the maximum tolerable dose of Metoprolol daily for 24 months. Regular outpatient follow-up visits to the research center. Their symptoms and Metoprolol dosage were recorded.
Details
| Lead sponsor | Xiangya Hospital of Central South University |
|---|---|
| Phase | Phase 4 |
| Status | NOT_YET_RECRUITING |
| Enrolment | 311 |
| Start date | 2025-02 |
| Completion | 2028-02 |
Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF)
- COPD (Chronic Obstructive Pulmonary Disease)
Interventions
- Different doses of Metoprolol.
Primary outcomes
- Composite endpoints (all-cause death and rehospitalization) — From enrollment to the end of treatment at 24 months.
Rehospitalization included readmission for heart failure and/or COPD.